HLA-DR2
{{cs1 config|name-list-style=vanc}}
{{Short description|Antigen serotype}}
HLA-DR2 (DR2) of the HLA-DR serotype system, is a broad antigen serotype that is now preferentially covered by HLA-DR15 and HLA-DR16 serotype group. This serotype primarily recognizes gene products of the HLA-DRB1*15 and HLA-DRB1*16 allele groups.
Serology
| border="0" cellspacing="0" cellpadding="0" align="center" style="text-align:center; background:#ffffff; margin-right: 1em; border:2px #e0e0ff solid;"
|+ DR15, DR2 and other serotype recognition of some DRB1*15 alleles[http://www.ebi.ac.uk/imgt/hla/allele.html derived from IMGT/HLA] | ||||
| style="background:#f0f0ff"
| style="width:60px" | DRB1* | style="width:60px" | DR15
| style="width:60px" | DR2 | style="width:60px" | DR16 | style="width:60px" | Sample | |
| style="background:#f0f0ff"
| allele | % | % | % | size (N) |
| style = "background:#e8e8f8" | 15:01 | 76 | 23 | 6428 | |
| style = "background:#e8e8f8" | 15:02 | 77 | 16 | 676 | |
| style = "background:#e8e8f8" | 15:03 | 81 | 13 | 286 | |
| style = "background:#e8e8f8" | 15:04 | >50 | 1 | ||
| style = "background:#e8e8f8" | 15:05 | >25 | 2 | ||
| style = "background:#e8e8f8" | 15:07 | >50 | 1 | ||
| style = "background:#e8e8f8" | | . | |||
| style="background:#f0f0ff"
| style="width:60px" | | style="width:60px" | DR16
| style="width:60px" | DR2 | style="width:60px" | DR15 | style="width:60px" | N | |
| style = "background:#e8e8f8" | 16:01 | 41 | 29 | 19 | 703 |
| style = "background:#e8e8f8" | 16:02 | 47 | 30 | 16 | 239 |
| style = "background:#e8e8f8" | 16:04 | >50 | 1 |
Disease associations
DR2 serotypes are associated with Goodpasture syndrome, systemic lupus erythematosus, multiple sclerosis,{{cite journal |vauthors=Stewart G, McLeod J, Basten A, Bashir H | title = HLA family studies and multiple sclerosis: A common gene, dominantly expressed. | journal = Hum Immunol | volume = 3 | issue = 1 | pages = 13–29 | year = 1981 | pmid = 7275697 | doi = 10.1016/0198-8859(81)90040-9}} narcolepsy, tuberculoid leprosy{{cite journal | doi = 10.1093/infdis/141.6.693 |vauthors=van Eden W, de Vries R, Mehra N, Vaidya M, D'Amaro J, van Rood J | title = HLA segregation of tuberculoid leprosy: confirmation of the DR2 marker. | journal = J Infect Dis | volume = 141 | issue = 6 | pages = 693–701 | year = 1980 | pmid = 6156220}} (multi-drug-resistant tuberculosis or leprosy),{{cite journal |vauthors=Singh M, Balamurugan A, Katoch K, Sharma SK, Mehra NK | title = Immunogenetics of mycobacterial infections in the North Indian population | journal = Tissue Antigens | volume = 69 | pages = 228–30 | year = 2007 | issue = Suppl 1 | pmid = 17445206 | doi = 10.1111/j.1399-0039.2006.77311.x}} ulcerative colitis (Japanese),{{cite journal |vauthors=Asakura H, Tsuchiya M, Aiso S, Watanabe M, Kobayashi K, Hibi T, Ando K, Takata H, Sekiguchi S | title = Association of the human lymphocyte-DR2 antigen with Japanese ulcerative colitis. | journal = Gastroenterology | volume = 82 | issue = 3 | pages = 413–8 | year = 1982 | doi = 10.1016/S0016-5085(82)80387-9 | pmid = 6947923| doi-access = free }} primary biliary cirrhosis and autoimmune hepatitis.{{cite journal |vauthors=Miyamori H, Kato Y, Kobayashi K, Hattori N | title = HLA antigens in Japanese patients with primary biliary cirrhosis and autoimmune hepatitis. | journal = Digestion | volume = 26 | issue = 4 | pages = 213–7 | year = 1983 | pmid = 6409699 | doi = 10.1159/000198892}} DR2 is also found in all patients that test positive for anti-Asn-RNA-synthetase and chronic interstitial lung disease.{{cite journal |vauthors=Hirakata M, Suwa A, Takada T, etal | title = Clinical and immunogenetic features of patients with autoantibodies to asparaginyl-transfer RNA synthetase | journal = Arthritis Rheum. | volume = 56 | issue = 4 | pages = 1295–303 | year = 2007 | pmid = 17393393 | doi = 10.1002/art.22506| doi-access = free }}
Genetic linkage
DR2 is linked to the HLA-DR51.